Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | MDM2 over exp TP53 wild-type |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
MDM2 over exp TP53 wild-type | neuroblastoma | sensitive | MX69 | Preclinical - Cell culture | Actionable | In a preclinical study, a neuroblastoma cell line over expressing MDM2 and wild-type for TP53 demonstrated sensitivity to treatment with MX69 in culture, resulting in decreased cell survival (PMID: 27666947). | 27666947 | |
MDM2 over exp TP53 wild-type | acute lymphoblastic leukemia | sensitive | MX69 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MX69 treatment induced cell death and inhibited cell growth in a TP53 wild-type acute lymphocytic leukemia cell line over expressing MDM2, and prolonged survival in xenograft models (PMID: 27666947). | 27666947 | |
MDM2 over exp TP53 wild-type | osteosarcoma | sensitive | RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type, MDM2 over-expressing osteosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... | |
MDM2 over exp TP53 wild-type | acute lymphoblastic leukemia | sensitive | AQ-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AQ-101 inhibited growth and induced apoptosis in acute lymphocytic leukemia (ALL) cell lines with wild-type TP53 and overexpression of MDM2 in culture, and inhibited development of leukemia in ALL cell line xenograft models (PMID: 29282301). | 29282301 | |
MDM2 over exp TP53 wild-type | ovarian clear cell carcinoma | predicted - sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment sensitized ovarian clear cell carcinoma cell lines harboring wild-type TP53 and MDM2 overexpression to T-cell mediated killing when co-cultured with T-cells, demonstrating decreased cell viability (PMID: 32655895). | 32655895 | |
MDM2 over exp TP53 wild-type | ovarian clear cell carcinoma | predicted - sensitive | KRT-232 + Pembrolizumab | Preclinical - Cell culture | Actionable | In a preclinical study, an ovarian clear cell carcinoma cell line harboring wild-type TP53 and MDM2 overexpression was sensitive to combination treatment with KRT-232 (AMG 232) and Keytruda (pembrolizumab) when co-cultured with T cells, demonstrating increased T-cell mediated cell death (PMID: 32655895). | 32655895 |